NCT06718192 A Randomized Controlled Trial to Evaluate the Effectiveness of Bleomycin and Cryotherapy in Treating Plantar Warts.
| NCT ID | NCT06718192 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | The Fourth Affiliated Hospital of Zhejiang University School of Medicine |
| Condition | Verruca Plantaris |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2024-12-25 |
| Primary Completion | 2025-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 70 participants in total. It began in 2024-12-25 with a primary completion date of 2025-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the efficacy of bleomycin and cryopreservation in the treatment of plantar verruca by dermoscopy and explore the influencing factors. Compare the safety, economic burden and impact on quality of life of the two treatments
Eligibility Criteria
Inclusion Criteria: Age 18-65 years old, gender is not limited; Consistent with the diagnosis of plantar warts; Volunteer for treatment and sign informed consent; Consent to photograph the lesion; The treatment target area can be selected (the target area must meet the following conditions: The distance between adjacent warts in the target area is \>0.5cm; The diameter of a single wart in the target area is ≤1.5cm, and/or the diameter of a wart mass is ≤1.5cm; The number of total warts/wart masses in the target area is ≤10). Exclusion Criteria: Patients who can't sign informed consent; Had previously received local treatment for common warts within 1 month; hiv-positive patient; Pregnant and lactating women; Has peripheral vascular disease; Allergic to bleomycin; People who are severely immunocompromised, or who are taking immunosuppressive drugs; Mental illness or cognitive incapacity; Other conditions deemed unsuitable for inclusion, such as inability to cooperate with follow-up, were considered by the researchers.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06718192 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Verruca Plantaris. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06718192 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06718192 currently recruiting?
Yes, NCT06718192 is actively recruiting participants. Contact the research team at liulunfei_zeyy@163.com for enrollment information.
Where is the NCT06718192 trial being conducted?
This trial is being conducted at Yiwu, China.
Who is sponsoring the NCT06718192 clinical trial?
NCT06718192 is sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. The trial plans to enroll 70 participants.